Untersuchung zum Effekt einer antibiotischen Therapie mit einem Chinolon der 4. Generation (Moxifloxacin) auf Metalloprotease 9 und Interleukin 6 im Wundsekret bei Patienten mit einem diabetischem Fußsyndrom Stadium 2 und 3. Investigation of the effect of antibiotic therapy with a 4th Generation quinolone (moxifloxacin) on matrixmetalloprotease 9 and interleukin-6 in wound secretions in patients with diabetic foot ulcers stage 2 and 3

Trial Profile

Untersuchung zum Effekt einer antibiotischen Therapie mit einem Chinolon der 4. Generation (Moxifloxacin) auf Metalloprotease 9 und Interleukin 6 im Wundsekret bei Patienten mit einem diabetischem Fußsyndrom Stadium 2 und 3. Investigation of the effect of antibiotic therapy with a 4th Generation quinolone (moxifloxacin) on matrixmetalloprotease 9 and interleukin-6 in wound secretions in patients with diabetic foot ulcers stage 2 and 3

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Jun 2013

At a glance

  • Drugs Moxifloxacin (Primary)
  • Indications Bacterial infections; Diabetic foot ulcer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top